Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
The Lancet ( IF 98.4 ) Pub Date : 2017-08-01 , DOI: 10.1016/s1470-2045(17)30318-2
Corinne Faivre-Finn ₁ , Michael Snee ₂ , Linda Ashcroft ₃ , Wiebke Appel ₄ , Fabrice Barlesi ₅ , Adityanarayan Bhatnagar ₆ , Andrea Bezjak ₇ , Felipe Cardenal ₈ , Pierre Fournel ₉ , Susan Harden ₁₀ , Cecile Le Pechoux ₁₁ , Rhona McMenemin ₁₂ , Nazia Mohammed ₁₃ , Mary O'Brien ₁₄ , Jason Pantarotto ₁₅ , Veerle Surmont ₁₆ , Jan P Van Meerbeeck ₁₇ , Penella J Woll ₁₈ , Paul Lorigan ₁₉ , Fiona Blackhall ₁₉ ,

Affiliation

Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK.
St James Institute of Oncology, Leeds, UK.
Manchester Academic Health Science Centre Trials Co-ordination Unit, The Christie NHS Foundation Trust, Manchester, UK.
Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Multidisciplinary Oncology & Therapeutic Innovations Department, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille, Marseille, France.
Department of Clinical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Canadian Cancer Trials Group, Princess Margaret Cancer Center, Toronto, ON, Canada.
GECP, Department of Medical Oncology, Institut Català'Oncologia, L'Hospitalet (Barcelona), Barcelona, Spain.
GFPC, Département d'Oncologie Médicale, Institut de Cancérologie Lucien Neuwirth, Saint-Étienne, France.
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Département d'Oncologie Radiothérapie, Gustave Roussy Cancer Campus, Villejuif, France.
Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK.
Department of Medicine, Royal Marsden NHS Foundation Trust, Surrey, UK.
Division of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada.
Department of Respiratory Medicine/Thoracic Oncology, Ghent University Hospital, Ghent, Belgium.
Thoracic Oncology, Antwerp University Hospital, Antwerp, Belgium.
Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.
Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer.

中文翻译：